Abstract 2790 The approval of second-generation tyrosine kinase inhibitors (TKIs) for the
first line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early
molecular parameters associated with inadequate responses to Imatinib Mesylate (IM).
Recent evidence suggests that CML patients presenting BCR-ABL/ABL IS levels> 10% after
3 months of IM or> 1% after 6 months of treatment have inferior outcomes in terms of both
overall survival (OS) and progression-free survival. We wanted to establish if high BCR-ABL …

The approval of three tyrosine kinase inhibitors (TKIs) for the first line treatment of Chronic
Myeloid Leukemia (CML) has generated an urgent need for molecular parameters predictive
of unfavorable therapeutic outcomes. Recent evidence suggests that failure to achieve early
molecular responses (ie BCR-ABL/ABL IS levels< 10% after 3 months or< 1% after 6 months
of TKI treatment) results in inferior rates of both overall and progression-free survival. With
the current study, we wanted to establish if high BCR-ABL transcripts at diagnosis would be …